Hybio Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hybio Pharmaceutical has a total shareholder equity of CN¥730.4M and total debt of CN¥1.9B, which brings its debt-to-equity ratio to 253.5%. Its total assets and total liabilities are CN¥3.1B and CN¥2.4B respectively.
Key information
253.5%
Debt to equity ratio
CN¥1.85b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥137.76m |
| Equity | CN¥730.42m |
| Total liabilities | CN¥2.39b |
| Total assets | CN¥3.12b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 300199's short term assets (CN¥548.0M) do not cover its short term liabilities (CN¥1.3B).
Long Term Liabilities: 300199's short term assets (CN¥548.0M) do not cover its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: 300199's net debt to equity ratio (234.6%) is considered high.
Reducing Debt: 300199's debt to equity ratio has increased from 73% to 253.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 300199 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 300199 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.2% per year.